Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study.
暂无分享,去创建一个
M. Uribe | L. Rodríguez-Fragoso | F. Sánchez-Ávila | G. García-Ramos | J. Poo | S. Aguilar-Castillo | Mario Fernández‐Zertuche | J. Góngora
[1] A. Mas. Hepatic Encephalopathy: From Pathophysiology to Treatment , 2006, Digestion.
[2] J. Talwalkar,et al. Influence of recent advances in medical management on clinical outcomes of cirrhosis. , 2005, Mayo Clinic proceedings.
[3] Dong Ki Lee,et al. Comparison of Rifaximin and Lactulose for the Treatment of Hepatic Encephalopathy: A Prospective Randomized Study , 2005, Yonsei medical journal.
[4] Ming Chen,et al. [Therapeutic effect of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy]. , 2005, Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA.
[5] R. Jalan,et al. Dispelling myths in the treatment of hepatic encephalopathy , 2005, The Lancet.
[6] M. Uribe,et al. Treatment of chronic portal—Systemic encephalopathy with vegetable and animal protein diets , 1982, Digestive Diseases and Sciences.
[7] H. Conn. Trailmaking and number-connection tests in the assessment of mental state in portal systemic encephalopathy , 1977, The American Journal of Digestive Diseases.
[8] H. Timmerman,et al. Effect of antibiotics, prebiotics and probiotics in treatment for hepatic encephalopathy. , 2005, Medical hypotheses.
[9] D. Hãussinger,et al. Nitrogen metabolism in liver : structural and functional organization and physiological relevance , 2005 .
[10] A. Whittemore,et al. Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[11] R. Esteban,et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. , 2004, Journal of hepatology.
[12] L. Gluud,et al. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials , 2004, BMJ : British Medical Journal.
[13] D. Häussinger,et al. Clinical Efficacy of L-Ornithine–L-Aspartate in the Management of Hepatic Encephalopathy , 2002, Metabolic Brain Disease.
[14] R. Butterworth. Pathophysiology of Hepatic Encephalopathy: A New Look at Ammonia , 2002, Metabolic Brain Disease.
[15] R. Butterworth,et al. L-Ornithine-L-Aspartate in Experimental Portal-Systemic Encephalopathy: Therapeutic Efficacy and Mechanism of Action , 1998, Metabolic Brain Disease.
[16] M. Uribe,et al. Hepatic encephalopathy: a review. , 2003, Annals of hepatology.
[17] J. Rodés,et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. , 2003, Journal of hepatology.
[18] D. Häussinger,et al. Management of hepatic encephalopathy , 2002, Journal of gastroenterology and hepatology.
[19] A. Burroughs,et al. Assessing health‐related quality of life pre– and post–liver transplantation: A prospective multicenter study , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[20] P. Thuluvath,et al. Effect of race on outcome of orthotopic liver transplantation: a cohort study , 2002, The Lancet.
[21] S. Brusilow. Hyperammonemic encephalopathy. , 2002, Medicine.
[22] A. Blei,et al. Hepatic Encephalopathy. , 2001, The American journal of gastroenterology.
[23] M. Hudson,et al. Effect of l-ornithine-l-aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial , 2000, Gut.
[24] William M. Lee,et al. Racial differences in responses to therapy with interferon in chronic hepatitis C , 1999, Hepatology.
[25] R. Butterworth,et al. L‐Ornithine‐L‐aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure , 1999, Hepatology.
[26] P. Malfertheiner,et al. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. , 1998, Journal of hepatology.
[27] M. Uribe,et al. Beneficial effect of carbohydrate maldigestion induced by a disaccharidase inhibitor (AO-128) in the treatment of chronic portal-systemic encephalopathy. A double-blind, randomized, controlled trial. , 1998, Scandinavian journal of gastroenterology.
[28] F. Gaunitz,et al. Treatment of cirrhotic rats with L-ornithine-L-aspartate enhances urea synthesis and lowers serum ammonia levels. , 1997, The Journal of pharmacology and experimental therapeutics.
[29] R Williams,et al. Treatment of hepatic encephalopathy. , 1997, The New England journal of medicine.
[30] G. Kircheis,et al. Therapeutic efficacy of L‐ornithine‐L‐aspartate infusions in patients with cirrhosis and hepatic encephalopathy: Results of a placebo‐controlled, double‐blind study , 1997, Hepatology.
[31] A. Herneth,et al. Newer Approaches to Therapy of Hepatic Encephalopathy , 1996, Seminars in liver disease.
[32] R. Hawkins,et al. Metabolic Abnormalities and Grade of Encephalopathy in Acute Hepatic Failure , 1994, Journal of neurochemistry.
[33] Beth Dawson,et al. Basic & Clinical Biostatistics , 1990 .
[34] F. Henry,et al. Cost effectiveness. , 1980, The Ohio State medical journal.